Hostname: page-component-8448b6f56d-42gr6 Total loading time: 0 Render date: 2024-04-19T16:54:44.083Z Has data issue: false hasContentIssue false

A Monoamine Oxidase Inhibitor (Niamid) in the Treatment of the Mentally Subnormal

Published online by Cambridge University Press:  08 February 2018

T. S. Davies*
Affiliation:
Llanfrechfa Grange Hospital, Newport, Mon

Extract

A clinical evaluation of the effects of a recently introduced monoamine oxidase inhibitor, N - isonicotinoyl - N1—(β - N - benzylcarboxamido - ethyl) hydrazine (Niamid, Pfizer, Ltd.) on certain types of mentally subnormal patients has been carried out over the past year.

Type
Original Articles
Copyright
Copyright © Royal College of Psychiatrists, 1961 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
Submit a response

eLetters

No eLetters have been published for this article.